KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Common Equity (2016 - 2025)

Historic Common Equity for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $3.4 billion.

  • Charles River Laboratories International's Common Equity fell 994.95% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 994.95%. This contributed to the annual value of $3.5 billion for FY2024, which is 375.66% down from last year.
  • Latest data reveals that Charles River Laboratories International reported Common Equity of $3.4 billion as of Q3 2025, which was down 994.95% from $3.4 billion recorded in Q2 2025.
  • Charles River Laboratories International's 5-year Common Equity high stood at $3.8 billion for Q3 2024, and its period low was $2.2 billion during Q1 2021.
  • In the last 5 years, Charles River Laboratories International's Common Equity had a median value of $3.2 billion in 2025 and averaged $3.1 billion.
  • Per our database at Business Quant, Charles River Laboratories International's Common Equity skyrocketed by 3225.06% in 2021 and then tumbled by 1223.29% in 2025.
  • Over the past 5 years, Charles River Laboratories International's Common Equity (Quarter) stood at $2.5 billion in 2021, then increased by 17.41% to $3.0 billion in 2022, then increased by 20.84% to $3.6 billion in 2023, then decreased by 3.76% to $3.5 billion in 2024, then decreased by 1.63% to $3.4 billion in 2025.
  • Its Common Equity stands at $3.4 billion for Q3 2025, versus $3.4 billion for Q2 2025 and $3.2 billion for Q1 2025.